NOI - Whole Genome Sequencing-Sickle Cell Patient

Project ID: 75N98026Q00368 FederalOpportunitiesSynopsis Solicitation

Overview

Agency	NIH Office of Logistics and Acquisition Operations
Deadline	05/29/26
Posted	05/15/26
Estimated Value	$200,000 - $500,000 (AI estimate)
Set Aside	None
NAICS	541990 - All Other Professional, Scientific, and Technical Services
PSC	B529 - Special Studies/Analysis- Scientific Data
Location	415 Main Street Cambridge, MA 02142 USA

Description

Primary Latest Change

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is (insert solicitation number) and the solicitation is issued as a Notice of Intent (NOI) of a non-competitive (notice of intent) combined synopsis solicitation to award a contract or purchase order without providing for full or open competition (including brand-name). This acquisition is conducted under the authority of the FAR Part 12.603 Streamlined solicitation for commercial products or commercial services and is not expected to exceed the simplified acquisition threshold, and the authority of 41 U.S.C. 1901 and the statutory authority of FAR 6.302-3(a)(2)(ii). The National Institutes of Health, Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order without providing for full and open competition (Including brand-name) to The Broad Institute, Inc. 415 Main Street Cambridge, MA 02142 for whole genome sequencing services. The purpose of this acquisition is to obtain high-quality whole genome sequencing (WGS) services for sickle cell disease (SCD) patient samples to support ongoing genomic research and predictive modeling efforts. The Broad Institute is uniquely positioned to perform this requirement due to its prior sequencing of this specific cohort and use of established sequencing and bioinformatics pipelines aligned with existing datasets. Use of another vendor would introduce data variability, require reprocessing or validation of prior datasets, and pose unacceptable technical and programmatic risk.

Summary (Newest Update)

Background The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order to The Broad Institute, Inc. for whole genome sequencing (WGS) services. This acquisition aims to support ongoing genomic research and predictive modeling efforts related to sickle cell disease (SCD). The Broad Institute is uniquely qualified due to its prior work with this specific cohort and established bioinformatics pipelines that align with existing datasets. Utilizing another vendor could introduce data variability and pose significant technical risks. Work Details The contractor will perform whole genome sequencing (WGS) on 250 additional SCD patient samples derived from well-characterized cohorts. The sequencing must achieve a minimum average depth of 60X coverage using high-quality, standardized library preparation protocols. The contractor is responsible for providing complete genomic datasets, including raw sequencing data and associated quality control metrics. All sequencing must meet established performance standards, including high alignment rates, low duplication rates, and consistent coverage metrics. The resulting data will be integrated with existing genomic datasets previously generated for this cohort to maintain comparability and support ongoing analyses. Period of Performance The contract will be performed from June 1, 2026, to September 30, 2026. Place of Performance All work will take place at the Broad Institute, located at 415 Main Street, Cambridge, MA 02142.

Contacts